Show simple item record

dc.contributor.authorGuglielmetti, L
dc.contributor.authorChiesi, S
dc.contributor.authorEimer, J
dc.contributor.authorDominguez, J
dc.contributor.authorMasini, T
dc.contributor.authorVaraine, F
dc.contributor.authorVeziris, N
dc.contributor.authorAder, F
dc.contributor.authorRobert, J
dc.date.accessioned2020-10-21T16:27:48Z
dc.date.available2020-10-21T16:27:48Z
dc.date.issued2020-07-23
dc.date.submitted2002-09-21
dc.identifier.urihttp://hdl.handle.net/10144/619734
dc.descriptionWe regret that this article is behind a paywall.en_US
dc.description.abstractDrug-resistant tuberculosis (TB) represents a substantial threat to the global efforts to control this disease. After decades of stagnation, the treatment of drug-resistant TB is undergoing major changes: two drugs with a new mechanism of action, bedaquiline and delamanid, have been approved by stringent regulatory authorities and are recommended by the WHO. This narrative review summarizes the evidence, originating from both observational studies and clinical trials, which is available to support the use of these drugs, with a focus on special populations. Areas of uncertainty, including the use of the two drugs together or for prolonged duration, are discussed. Ongoing clinical trials are aiming to optimize the use of bedaquiline and delamanid to shorten the treatment of drug-resistant TB.en_US
dc.language.isoenen_US
dc.publisherFuture Medicineen_US
dc.titleBedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspectiveen_US
dc.identifier.journalFuture Microbiologyen_US


This item appears in the following Collection(s)

Show simple item record